Investors poured into Moderna and Merck on Wednesday after the two pharmaceutical giants announced a major victory in their fight against skin cancer. A late stage clinical trial revealed that a personalized mRNA vaccine called intismeran, used in tandem with Merck’s immunotherapy drug Keytruda, significantly prevented melanoma from returning in high risk patients. The results sent shockwaves through the stock market, pushing Moderna shares toward a two year high and driving Merck to an all time peak.
Unlike standard cancer treatments that take a broad approach, this new therapy is entirely bespoke. Doctors surgically remove a piece of a patient’s tumor and sequence its DNA to find unique mutations. This information is then used to create a customized vaccine that trains the patient’s own immune system to hunt down and destroy any remaining cancer cells. According to Moderna President Stephen Hoge, this marks the first time an individualized treatment has shown such statistically significant improvement over existing checkpoint inhibitors like Keytruda alone.
The financial impact of the news was immediate and dramatic. Moderna saw its market capitalization jump by roughly 30 billion dollars as trading volumes skyrocketed far beyond their usual averages. The success also lifted the broader biotech sector, helping the Nasdaq Biotechnology Index climb to a record high as analysts grew optimistic about the future of personalized medicine.
Looking ahead, the companies have already begun talks with regulatory agencies and hope to bring the treatment to market as early as next year. While these current results focused on melanoma, Moderna and Merck are not stopping there. They are currently conducting further trials to see if this same tailored mRNA approach can be effectively used to treat other aggressive forms of cancer, including lung, pancreatic, and breast cancers.